NCT05448482

Brief Summary

This prospective study is conducted on female patients presenting with SUI at Alexandria main university hospital. Patients with neurogenic voiding dysfunction, history of anti-incontinence surgery, urge-predominant MUI, urogenital cancer, pelvic irradiation, body mass index more than 40 kg/m2 and more than stage 1 POP are excluded. Patients are randomized into 2 groups, one group will be subjected to h\_TOT, and the second group to conventional TOT. Patients are subjected to PGI and UDI-6 questionnaires and a urodynamic study before and 6 months after the both surgery. Success is defined as: no subjective complaint of SUI, negative cough stress test and no leakage on UDS.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 5, 2021

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

July 2, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 7, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 5, 2023

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2023

Completed
Last Updated

July 7, 2022

Status Verified

March 1, 2022

Enrollment Period

2 years

First QC Date

July 2, 2022

Last Update Submit

July 2, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Dryness

    Absence of clinical and urodynamic stress incontinence

    6 months

Study Arms (2)

Hybrid transobturator tape

EXPERIMENTAL

Anterior rectus fascia will be exposed and an approximately 8-10 cm × 1 cm strip of rectus fascia will be marked out. The sling will be harvested using sharp dissection. Thereafter, a Polyprolene monofilamentous mesh of 15 cm x 1 cm will be sutured to each edge of the rectus fascia sling that had been harvested. Then, a 2-cm midline incision over the anterior vaginal wall at the level of mid-urethra. A combination of blunt and sharp dissection will be carried out to the obturator foramen bilaterally. Next, a stab incision will be made at a point approximately 2.5 cm infero-lateral to the pubic tubercle bilaterally, corresponding to the level of clitoris. A trocar will be passed through each obturator foramen (outside-in) and the edge of the mesh will be retracted through the incision. Next, the retraction of both meshes will continue until the rectus fascia sling remain flushed with the urethra.

Procedure: Transobturator tape

Conventional transobturator tape

ACTIVE COMPARATOR

The conventional mesh using mid urethral sling through the trans obturator route

Procedure: Transobturator tape

Interventions

Mid urethral sling for treatment of female stress urinary incontinence

Conventional transobturator tapeHybrid transobturator tape

Eligibility Criteria

Age20 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinically proven SUI or stress-predominant mixed urinary incontinence by cough stress test.

You may not qualify if:

  • Patients with neurogenic voiding dysfunction.
  • History of anti-incontinence surgery.
  • Presence of urge-predominant mixed urinary incontinence.
  • Peripheral neuropathy.
  • Multiple sclerosis.
  • History of urogenital cancer.
  • Pelvic irradiation
  • Body mass index more than 40 kg/m2
  • The presence of more than stage 2 pelvic organ prolapse as per pelvic organ prolapse quantification (POP-Q) system score.
  • Active urinary tract infection
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alexandria Faculty of Medicine

Alexandria, Egypt

RECRUITING

MeSH Terms

Interventions

Suburethral Slings

Intervention Hierarchy (Ancestors)

Prostheses and ImplantsEquipment and Supplies

Central Study Contacts

Mohammad A. Alkhawalka, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 2, 2022

First Posted

July 7, 2022

Study Start

January 5, 2021

Primary Completion

January 5, 2023

Study Completion

January 15, 2023

Last Updated

July 7, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations